The European Medicines Agency (EMA) will proactively publish clinical trial data and enable access to full data sets by interested parties.

A number of practical and policy issues need to be addressed before complex data sets can be made available. The EMA will hold a workshop in November to listen to the views, interests and concerns from a broad range of institutions, groups and individuals. The results will help it define the modalities of proactive access to clinical trial data, in an open and transparent forum. Registration is open until Oct. 31, with attendance limited to 150.